Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells

Cancer Research

Volumn 57, Issue 17, 1997, Pages 3818-3822

  Marth, Christian ^a,b   Zeimet, Alain G ^a   Widschwendter, Martin ^a   Ludescher, Christoph ^a   Kærn, Janne ^b   Tropé, Claes ^b   Gastl, Günther ^a   Daxenbichler, Günter ^a   Dapunt, Otto ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; DOCETAXEL; PACLITAXEL;

ARTICLE; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RNA SYNTHESIS; RNA TRANSCRIPTION; STEROIDOGENESIS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CA-125 ANTIGEN; CELL DIVISION; CYTOSOL; FEMALE; HUMANS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PACLITAXEL; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 0030848536     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bast, R. C., Klug, T. L., St. John, E., Jenison, E., Niloff, J. M., Lazarus, H., Berkowta, R. S., Leavitt, T., Griffiths, C. T., Parker, L., Zurawski, V. R., and Knapp, R. C. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med., 309: 883-887, 1983.
2. Fish, R. G., Shelley, M. D., Maughan, T., Rocker, I., and Adams, M. The clinical value of serum CA-125 levels in ovarian cancer patients receiving platinum therapy. Eur. J. Cancer & Clin. Oncol., 23: 831-835, 1987.
3. Makar, A. P., Kristensen, G. B., Børmer, O. P., and Tropé, C. G. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy. Gynecol. Oncol., 49: 73-79, 1993.
4. Rustin, G. J. S., Nelstrop, A. E., McClean, P., Brady, M. F., McGuire, W. P., Hoskins, W. J., Mitchell, H., and Lambert, H. E. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J. Clin. Oncol., 14: 1545-1551, 1996.
5. Van der Burg, M. E. L., Lammes, F. B., Van Putten, W. L. J., and Stoter, G. Ovarian cancer: the prognostic value of the serum half life of CA-125 during induction chemotherapy. Gynecol. Oncol., 30: 307-312, 1988.
6. Buller, R. E., Vasilev, S., and DiSaia, P. J. CA 125 kinetics: a cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s. Am. J. Obstet. Gynecol., 174: 1241-1254, 1996.
7. Markman, M. CA-125: an evolving role in the management of ovarian cancer. J. Clin. Oncol., 14: 1411-1412, 1996.
8. Marth, C., Zeimet, A. G., Böck, G., and Daxenbichler, G. Modulation of tumour marker CA-125 expression in cultured ovarian carcinoma cells. Eur. J. Cancer, 28A: 2002-2006, 1992.
9. Marth, C., Fuith, L. C., Böck, G., Daxenbichler, G., and Dapunt, O. Modulation of ovarian carcinoma tumor marker CA-125 by interferon-γ Cancer Res., 49: 6538-6542, 1989.
10. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med., 334: 1-6, 1996.
11. Van der Burg, M. K. L., Myles, J. D., Hoskins, P. J., Ten Bokkel Huinik, W. W., and Eisenhauer, E. CA 125 is an unreliable marker for monitoring response to taxol therapy in patients with relapsed ovarian cancer. Eur. J. Cancer. 29A: 133, 1993.
12. Schiff, P. B., and Horwitz, S. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA, 77: 1561-1565, 1980.
13. Lee, L. F., Schuerer, C. C., Lofquist, A. K., van Haaften-Day, C., Ting, J. P. Y., White, C. M., Martin, B. K., and Haskill, J. S. Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer. Cancer Res., 56: 1303-1308, 1996.
14. Marth, C., Lang, T., Widschwendter, M., Müller-Holzner, E., and Daxenbichler, G. Effects of taxol on choriocarcinoma cells. Am. J. Obstet. Gynecol., 173: 1835-1842, 1995.
15. Francis, P., Schneider, J., Hann, L., Balmaceda, C., Barakat, R., Philips, M., and Hakes, T. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J. Clin. Oncol., 12: 2301-2308, 1994.
16. Slezak, S. E., and Horan, P. K. Cell mediated cytotoxicity: a highly sensitive and informative flow cytometric assay. J. Immunol. Methods, 117: 205-214, 1989.
17. Chen, T. T., Massey, P. J., and Caudle, M. R. The inhibitory action of taxol on granulosa cell steroidogenesis is reversible. Endocrinology, 134: 2178-2183, 1994.
18. Cameron, M. R., Caudle, M. R., Sullivan, W. R., Peluso, J. J., and Wimalasena, J. The steroidogenic and morphological effects of paclitaxel on cultured ovarian cancer cells. Oncol. Res., 7; 145-156, 1995.
19. Sohell, H. M. Actinomycin, and DNA transcription. Proc. Natl. Acad. Sci. USA, 82: 5238-5331, 1985.
20. Martin, S. J., Lennon, S. V., Bonham, A. M., and Cotter, T. G. Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis. J. Immunol., 145: 1859-1867, 1990.
21. Masuho, Y., Zalutsky, M., Knapp, R. C., and Bast, R. C., Jr. Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. Cancer Res., 44: 2813-2819, 1984.
22. Kurachi, H., Adachi, H., Morishige, K. I., Adachi, K., Takeda, T., Homma, H., Yamamoto, T., and Miyake, A. Transforming growth factor-α promotes tumor markers secretion from human ovarian cancers in vitro. Cancer (Phila.), 78: 1049-1054, 1996.
23. Zeimet, A. G., Marth, C., Offner, F. A., Obrist, P., Uhl-Steidl, M., Feichtinger, H., Stadlmann, S., Daxenbichler, G., and Dapunt, O. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol. Oncol., 62: 384-389, 1996.
24. Karlan, B. Y., Amin, W., Casper, S. E., and Liltlefield, B. A. Hormonal regulation of CA-125 tumor marker expression in human ovarian carcinoma cell: inhibition by glucocorticoid. Cancer Res., 48: 3502-3505, 1988.
25. Marth, C., Lang, T., Koza, A., Mayer, I., and Daxenbichler, G. Transforming growth factor-β (TGF-β) and ovarian carcinoma cells: regulation of proliferation and surface antigen expression. Cancer Lett., 51: 221-225, 1990.
26. Pearl, M. L., Yashar, C. M., Johnston, C. M., Reynolds, R. K., and Roberts, J. A. Exponential regression of CA-125 during salvage treatment of ovarian cancer with taxol. Gynecol. Oncol., 53: 339-343, 1994.
27. Pujade-Lauraine, E., Piccart, M., Rustin, G., Lhommé, C., Gore, M., Ten Bokkel Huining, W., Fumoleau, P., Van Osteroom, A., Kerweij, Y. A., Kaye, S., Belpomme, D., Van Glabbeke, M., Wanders, R., Chevallier, B., and Franklin, H. Comparison of CA 125 kinetics and WHO criteria to evaluate chemotherapy response (R): an EORTC ovarian cancer study with taxotere. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 13: 269, 1994